AstraZeneca
  • Bookmark This Page
  • Print This Page
  • Share with a Friend
Change Text Size
Change Text Size
Change Text Size
Change Text Size
Change Text Size

Asthma screening events

Parents may have noticed that their child has had problems breathing or they may have heard that asthma often goes undiagnosed. So, how can they find out if their child has asthma? A free asthma screening can be their first step.

AstraZeneca has teamed up with the American College of Allergy, Asthma and Immunology (ACAAI) to provide asthma-screening programs in patients' communities around the country. This simple screening can indicate if a child may have asthma or asthma-like symptoms.

To help your patient find a screening in your area, please choose your state below. If you don't see one in a nearby community, you can talk with ACAAI about developing this service. Or, call 312-558-1175 or e-mail at asthmascreening@pcipr.com.

Nationwide Asthma Screening Program

Select a state to view upcoming events

State:    

“Next” Button
Learn about custom patient education

Indication and Important Safety Information

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

[Please see accompanying full Prescribing Information (PDF).]